Patents by Inventor Michela Silacci

Michela Silacci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-fynomer conjugates
    Patent number: 10323095
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland Newman, Steve Granger, Michael Lyman, Dragan Grabulovski, Richard Woods, Michela Silacci, Wenjuan Zha, Isabella Attinger-Toller
  • ANTIBODY-FYNOMER CONJUGATES
    Publication number: 20170081412
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Application
    Filed: March 16, 2015
    Publication date: March 23, 2017
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland NEWMAN, Steve GRANGER, Michael LYMAN, Dragan GRABULOVSKI, Richard WOODS, Michela SILACCI, Wenjuan ZHA, Isabella ATTINGER-TOLLER
  • Antibodies against Tenascin-C
    Patent number: 7968685
    Abstract: Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: June 28, 2011
    Assignee: Philogen S.p.A.
    Inventors: Simon Brack, Michela Silacci, Dario Neri
  • Antibodies Against Tenascin-C
    Publication number: 20080056997
    Abstract: Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.
    Type: Application
    Filed: October 31, 2005
    Publication date: March 6, 2008
    Applicant: PHILOGEN S.P.A.
    Inventors: Simon Brack, Michela Silacci, Dario Neri